Welcome to our dedicated page for MICROBIX BIOSYSTEMS news (Ticker: MBXBF), a resource for investors and traders seeking the latest updates and insights on MICROBIX BIOSYSTEMS stock.
Microbix Biosystems Inc. (MBXBF) is a life sciences innovator, manufacturer, and exporter that focuses on biological products for the global diagnostics industry. News about Microbix often centers on developments in its antigen manufacturing capabilities, expansion of its quality assessment products (QAPs™), and updates on its reference materials (QUANTDx™) used by clinical laboratories and diagnostics makers.
Investors and industry professionals following Microbix news can expect updates on product commercialization, such as the company’s recombinant nucleocapsid antigen of the SARS-CoV-2 virus for use in QAPs and by test manufacturers. Coverage may also include announcements related to its expertise in native viral antigens, new applications of its QAPs and reference materials in proficiency testing and external quality assessment programs, and developments in reagents and media that support diagnostic testing, including DxTM™ for patient-sample collection.
Microbix news releases also address regulatory and disclosure matters, including interactions with securities regulators about continuous disclosure practices and the use of non-IFRS financial measures. These items provide context about how the company presents its financial and operational information to investors.
Because Microbix supplies antigens to approximately 100 diagnostics makers and distributes QAPs in over 30 countries, its news can be relevant to stakeholders across the diagnostics value chain. By monitoring this page, readers can review announcements about product launches, manufacturing capabilities, quality and regulatory accreditations, and other corporate communications that shape the company’s role in the diagnostics and life sciences sectors.
Microbix Biosystems (MBXBF) will present to investors at the Muskoka Capital Event in Minett, Ontario, from September 25 to 27, 2025. CEO Cameron Groome and Director of Product Management Pavel Zhelev plan to conduct 18 one-on-one meetings with growth-company investors during the formal part of the conference. Presentation slides will be posted on the company’s website alongside other business information and financial disclosures.
Microbix is a Canadian life sciences company with fiscal 2025 revenues of C$18.6 million and about 120 employees, providing proprietary antigens, QAPs quality assessment products, and QUANTDx reference materials to diagnostics manufacturers and clinical laboratories in more than 30 countries.
Microbix Biosystems (MBXBF) has completed formal qualification as a supplier to five major in-vitro diagnostics (IVD) manufacturers that are each among the ten largest Dx Test-Makers by revenue. These companies have completed multi-step audits of Microbix’s manufacturing, quality, ISO compliance, and related systems.
Qualification enables Microbix to supply products across its antigens, QAPs, ONBOARDx kits, QUANTDx reference materials, and reagents. While this does not guarantee contracts, Microbix expects improved access to new project opportunities with these large manufacturers and believes this vetted status may also support business with smaller diagnostics companies. The company reported C$ 18.6 million of revenue in its latest fiscal year 2025.
Microbix Biosystems (TSX:MBX, OTCQX:MBXBF) reported Q3 fiscal 2026 revenue of $4.1 million, up 17% year-over-year, driven by 20% growth in antigen sales to $2.2 million and 13% growth in QAPs to $1.7 million. Q3 gross margin rose to 54% from 41%.
According to Microbix, Q3 operating and net loss narrowed to $0.81 million from $1.64 million, and cash used in operations improved to $0.47 million from $1.92 million. For the nine months, revenue fell 21% to $11.7 million, mainly from a >$4 million decline in China antigen sales, contributing to a YTD net loss of $3.4 million. The company ended Q3 with $7.2 million in cash, a current ratio of 6.89, and a debt-to-equity ratio of 0.40.
Microbix Biosystems (TSX:MBX, OTCQX:MBXBF) plans to file its financial statements, management discussion and analysis, and news release for Q3 fiscal 2026 (quarter ended June 30, 2026) before the start of trading on August 13, 2026.
On the same day at 10:00 AM ET, Microbix intends to host a results webinar featuring its CEO, CFO, and COO, moderated by Adelaide Capital, with live access via Zoom registration and YouTube, and a replay to follow. The company also highlights its 2025 revenues of C$18.6 million and its global portfolio of diagnostic ingredients, quality assessment products (QAPs, QUANTDx), and other proprietary life sciences technologies.
Microbix (OTCQX:MBXBF) reported Q2 2026 revenue of $3.38 million, down 37% year-over-year, and H1 2026 revenue of $7.60 million, down 33%. Gross margin fell to 48% in Q2 and 44% in H1, leading to net losses of $1.43 million in Q2 and $2.60 million in H1.
Antigen sales to China dropped by over $4 million in H1, while antigen sales to other customers grew. Operating expenses declined slightly. At March 31, 2026, cash was $8.13 million, current ratio 5.35, and debt-to-equity 0.41. Management continues to pursue new clients and targets full-year 2026 results in line with MD&A guidance.
Microbix (OTCQX:MBXBF, TSX:MBX) said it will file Q2 fiscal 2026 financial statements, MD&A and a results news release prior to the start of trading on May 14, 2026. A webinar discussion with CEO, CFO and COO is scheduled for 10:00 AM ET that day.
Investors may register via Zoom or watch a live stream and later replay on Adelaide Capital's YouTube channel.
Microbix (OTCQX:MBXBF, TSX:MBX) says a client will present results using Microbix quality assessment products (QAPs) for HPV detection at 2026 PASCV, April 29–May 1, 2026 in Clearwater Beach, FL. The client poster reports 100% detection, strong reproducibility, tight standard deviations, and room-temperature stability for 12 days.
Microbix will not attend the meeting. The poster, authored by Abbott authors with Microbix support, will be posted at the company's website. Purchase enquiries: customer.service@microbix.com.
Microbix (OTCQX:MBXBF, TSX:MBX) is releasing three episodes of season two of its podcast Diagnostics: Beyond the Lab on April 20, 2026. Hosted by CEO Cameron Groome, each ~60-minute episode features diagnostics experts discussing adoption, quality assessment, and community engagement.
Guests include James Yantzi (Seegene Canada), Dr. Simon Patton (EMQN), and Dr. Tanya Applegate with Stacey Foster-Rampant (Kirby Institute). Episodes are available this spring on microbix.com and major podcast platforms; season one remains accessible via the same links.
Microbix (OTCQX:MBXBF, TSX:MBX) will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21–22, 2026. COO Dr. Ken Hughes will present in person on April 22 at 2:00 p.m. ET and the management team will hold one-on-one investor meetings. Presentation slides will be available for download at the company website.
Microbix (OTCQX:MBXBF) will exhibit and present at ESCMID Global 2026 (April 17–21, Munich), showcasing its QAP™ whole-process quality controls for RNA-based assays and QUANTDx quantified reference materials.
Microbix will present a poster on a non-infectious phage-encapsulated RNA HCV mimetic validated as a safe, stable, whole-process control.